Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This article presents a collection of interdisciplinary studies by Brazilian researchers that address various societal issues to contribute to the nation's social and scientific development; it reports no new results.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study found that administering dutasteride did not change spermatogenesis or oxidative stress levels in rat testes, though further research is needed to confirm these findings.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This research highlights the potential of using nanomaterials with advanced reactive oxygen properties to target oxidative stress in hair follicle tissue, which is associated with androgenetic alopecia, addressing a gap in the current understanding of AGA treatments.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This study found that in men with androgenetic alopecia, a combination therapy of oral dutasteride and minoxidil was well tolerated and resulted in hair stabilization for nearly all participants by month 6, with 71.4% showing improvement by month 9.

This paper evaluates the therapeutic response of androgenetic alopecia to topical application of specific compounds using digital drug delivery but reports no new clinical results.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study identified ISX9 as a novel agonist of the Wnt/β‐catenin pathway, which promoted hair regrowth in mice and may offer a therapeutic approach for alopecia.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

This study shares preliminary findings that roxithromycin treatment tendentially increased hair shaft production and altered the hair follicle microbiota in human hair ex vivo, with substantial inter-individual differences observed.

In this study, researchers reported that while conventional treatments like topical minoxidil remain fundamental for androgenetic alopecia, guidelines increasingly support low-dose oral minoxidil and dutasteride, though their recommendations vary. Personalized multimodal treatment strategies and regular follow-ups are essential in clinical practice.

This review discusses inflammatory and medication-related skin conditions associated with kidney disease and emphasizes the importance of timely referral to nephrology, reporting no new clinical results.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.